PolarityTE provided a business update and reported financial results for the quarterly period ended June 30, 2022.
Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336.
Fluidx Medical’s GPX Embolic Material Yields Promising Results for Oncology Uses
Modern design advances patient care by combining hemostasis with innovative cooling capability
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.
Soft Cell Labs announces new Urinary Tract Infection Test
ELITechGroup to provide contract development and manufacturing services for HypoxE® IVD Tests designed for Selectra Pro family of clinical chemistry analyzers
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
New 3M will remain a leading global material science innovator serving diverse end markets, with science and technology, manufacturing, global capabilities, and iconic brands
Tillis and Leahy Introduce Bipartisan Legislation to Improve Patent Quality
UTMD achieved second calendar quarter (2Q) and first half (1H) 2022 financial results better than those anticipated in its beginning of year projections.